公开(公告)号：US20240360195A1

公开(公告)日：2024-10-31

申请号：US18579283

申请日：2022-07-13

Applicant: Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)

Inventor： Reinhard Zeidler

IPC: C07K14/705 ,  A61K38/00

CPC classification number: C07K14/70503 ,  A61K38/00 ,  C07K2317/14 ,  C07K2317/55 ,  C07K2317/565

Abstract: The present invention relates to a novel dimer composed of a first Fab monomer and a second Fab monomer, each Fab monomer comprising a VH and a VL region, wherein two of such VH or VL regions are covalently linked by a disulfide bond between an additional non-naturally occurring cysteine residue at their respective N-termini.

公开(公告)号：US12129292B2

公开(公告)日：2024-10-29

申请号：US17438657

申请日：2020-02-26

Applicant: Janssen Biotech, Inc.

Inventor： Kristopher Barnthouse ,  Subinay Ganguly ,  Maarten Groeneveld ,  Manuel Lopez ,  Michael Nedved ,  Kevin D. Smith

IPC: C07K16/24

CPC classification number: C07K16/241 ,  C07K2317/14 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Presented here are methods for producing a recombinant anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:38 and a light chain (LC) comprising SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.

公开(公告)号：US12122825B2

公开(公告)日：2024-10-22

申请号：US17438684

申请日：2020-02-26

Applicant: Janssen Biotech, Inc.

Inventor： Kristopher Barnthouse ,  Subinay Ganguly ,  Maarten Groeneveld ,  Manuel Lopez, Jr. ,  Michael Nedved ,  Kevin D. Smith

IPC: C07K16/24

CPC classification number: C07K16/241 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92

Abstract: Presented here are methods for producing a recombinant anti-TNF antibody having a heavy chain (HC) comprising SEQ ID NO:38 and a light chain (LC) comprising SEQ ID NO:37 and compositions comprising the recombinant anti-TNF antibody.

公开(公告)号：US20240344102A1

公开(公告)日：2024-10-17

申请号：US18431564

申请日：2024-02-02

Applicant: Merus N.V.

Inventor： Cornelis Adriaan DE KRUIF ,  Linda Johanna Aleida Hendriks ,  Ton Logtenberg

IPC: C12P21/00 ,  A61K39/395 ,  A61K39/40 ,  C07K16/12 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/36 ,  C07K16/46 ,  A61K39/00

CPC classification number: C12P21/005 ,  A61K39/395 ,  A61K39/3955 ,  A61K39/40 ,  C07K16/12 ,  C07K16/1278 ,  C07K16/1282 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/2809 ,  C07K16/283 ,  C07K16/2866 ,  C07K16/2896 ,  C07K16/36 ,  C07K16/468 ,  A61K2039/507 ,  C07K2317/14 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/56 ,  C07K2317/94

Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.

公开(公告)号：US20240343808A1

公开(公告)日：2024-10-17

申请号：US18392954

申请日：2023-12-21

Applicant: Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Inventor： Gordon James Freeman ,  Arlene Helen Sharpe ,  Gerhard Johann Frey ,  Hwai Wen Chang ,  Jennifer Marie Mataraza ,  Glenn Dranoff

IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61N5/10 ,  C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/3046 ,  C07K16/3053 ,  C07K16/3069 ,  G01N33/57492 ,  A61K2039/505 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70532

Abstract: Antibody molecules that specifically bind to PD-L1 are disclosed. Combination therapies comprising the anti-PD-L1 antibody molecules are also disclosed. The anti-PD-L1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：US20240343781A1

公开(公告)日：2024-10-17

申请号：US18291530

申请日：2022-07-22

Applicant: The Trustees of Columbia University in the City of New York

Inventor： David D. HO ,  Yaoxing HUANG ,  Lihong LIU ,  Manoj S. NAIR ,  Jian YU ,  Sho IKETANI

IPC: C07K16/10 ,  A61P31/20

CPC classification number: C07K16/1003 ,  A61P31/20 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The subject matter described herein relates to engineered monoclonal antibodies, derived from antibodies isolated from human patients, neutralizing a SARS-CoV-2 virus, its variants, or related coronaviruses.

公开(公告)号：US12116607B2

公开(公告)日：2024-10-15

申请号：US15254027

申请日：2016-09-01

Applicant: Ablynx N.V.

Inventor： Peter Schotte ,  Patrick Stanssens ,  Christine Labeur ,  Jean-Luc Jonniaux ,  Marc Jozef Lauwereys

IPC: C12P21/00 ,  C07K16/00 ,  C07K16/18 ,  C07K16/28

CPC classification number: C12P21/005 ,  C07K16/00 ,  C07K16/18 ,  C07K16/2875 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/35 ,  C07K2317/56 ,  C07K2317/569 ,  C07K2317/624 ,  C07K2317/626

Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.

公开(公告)号：US20240327785A1

公开(公告)日：2024-10-03

申请号：US18543857

申请日：2023-12-18

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lynn Macdonald ,  Sean Stevens ,  Cagan Gurer ,  Andrew J. Murphy ,  Karolina A. Meagher

IPC: C12N5/0735 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C07K16/18 ,  C07K16/46 ,  C12N15/10 ,  C12N15/85

CPC classification number: C12N5/0606 ,  A01K67/0275 ,  A01K67/0278 ,  C07K16/00 ,  C07K16/18 ,  C07K16/461 ,  C07K16/462 ,  C12N15/10 ,  C12N15/8509 ,  A01K2207/15 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/02 ,  A01K2267/0381 ,  C07K2317/10 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/50 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/64

Abstract: Genetically modified mice are provided that express human λ variable (hVλ) sequences, including mice that express hVλ sequences from an endogenous mouse λ light chain locus, mice that express hVλ sequences from an endogenous mouse κ light chain locus, and mice that express hVλ sequences from a transgene or an episome wherein the hVλ sequence is linked to a mouse constant sequence. Mice are provided that are a source of somatically mutated human λ variable sequences useful for making antigen-binding proteins. Compositions and methods for making antigen-binding proteins that comprise human λ variable sequences, including human antibodies, are provided.

公开(公告)号：US20240327496A1

公开(公告)日：2024-10-03

申请号：US18293889

申请日：2022-07-29

Applicant: Pfizer Inc.

Inventor： Kalpanie Ruwanmali Bandara ,  Kathryn Mary Beal ,  John Joseph Scarcelli ,  Lin Zhang

IPC: C07K16/00 ,  C12N15/85

CPC classification number: C07K16/00 ,  C12N15/85 ,  C07K2317/14 ,  C07K2319/00 ,  C12N2800/30

Abstract: Vectors and nucleic acid constructs for improved antibody production are provided. Also provided are methods of making and using the vectors and constructs.

公开(公告)号：US12103975B2

公开(公告)日：2024-10-01

申请号：US17217706

申请日：2021-03-30

Applicant: Genentech, Inc.

Inventor： Martin Gawlitzek ,  Shun Luo ,  Christina Teresa Bevilacqua

IPC: C07K16/28 ,  C07K14/705 ,  C07K16/18 ,  C07K16/22 ,  C12N5/00

CPC classification number: C07K16/2878 ,  C07K14/70575 ,  C07K16/18 ,  C07K16/22 ,  C12N5/0018 ,  C12N5/0043 ,  C07K2317/14 ,  C07K2319/30 ,  C12N2500/32 ,  C12N2500/33 ,  C12N2500/90

Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.